<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To evaluate the role of <z:chebi fb="2" ids="2948">azathioprine</z:chebi> as an immunosuppressive for steroid-resistant autoimmune <z:hpo ids='HP_0000554'>uveitis</z:hpo> (AIU) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Patients using oral <z:chebi fb="2" ids="8378">prednisolone</z:chebi> for active AIU without clinical response were recruited </plain></SENT>
<SENT sid="2" pm="."><plain>A standard protocol of oral <z:chebi fb="2" ids="8378">prednisolone</z:chebi> and <z:chebi fb="2" ids="2948">azathioprine</z:chebi> was used </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Twenty-seven patients participated in the study: 3 with <z:hpo ids='HP_0012122'>anterior uveitis</z:hpo>, 1 pars planitis, 4 idiopatic <z:hpo ids='HP_0012121'>panuveitis</z:hpo>, 8 Vogt-Koyonagi-Harada syndrome, 3 Behcet disease, and 8 choroidoretinopathies </plain></SENT>
<SENT sid="4" pm="."><plain>Complete response was observed in 92% </plain></SENT>
<SENT sid="5" pm="."><plain>Eleven patients had well-tolerated minor side effects </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: <z:chebi fb="2" ids="2948">Azathioprine</z:chebi> is safe and effective in controlling steroid-resistant AIU </plain></SENT>
</text></document>